(Q46150327)

English

A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis

scientific article published in March 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19165648

A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19165648

0 references

1 reference

based on heuristic

inferred from title

author name string

L E Dahlberg

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19165648

I Holme

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19165648

K Høye

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19165648

B Ringertz

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19165648

publication date

1 March 2009

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19165648

Scandinavian Journal of Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19165648

38

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19165648

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19165648

133-143

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19165648

Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Celecoxib versus diclofenac in the management of osteoarthritis of the knee

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Reliability, validity, and responsiveness of severity of dyspepsia assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Anemia and decline in physical performance among older persons

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Anemia is associated with disability and decreased physical performance and muscle strength in the elderly

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Impact of anemia and cardiovascular disease on frailty status of community-dwelling older women: the Women's Health and Aging Studies I and II

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Celecoxib for the prevention of sporadic colorectal adenomas

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Celecoxib for the prevention of colorectal adenomatous polyps

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis

1 reference

https://api.crossref.org/works/10.1080%2F03009740802419065

21 January 2018

Identifiers

10.1080/03009740802419065

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19165648

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19165648

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46150327&oldid=2095024080"